T cells in atherosclerosis

International Immunology

Volumn 25, Issue 11, 2013, Pages 615-622

  Tse, Kevin ^a,b   Tse, Harley ^c   Sidney, John ^b   Sette, Alex ^b   Ley, Klaus ^b  

^a UCSD MEDICAL CENTER   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Inflammation; T cell

Indexed keywords

AUTOANTIGEN; GAMMA INTERFERON; GLYCOLIPID; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 25; INTERLEUKIN 27; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HELPER CELL; HUMAN; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL;

ATHEROSCLEROSIS; INFLAMMATION; T CELL;

ANIMALS; ATHEROSCLEROSIS; HUMANS; T-LYMPHOCYTES;

EID: 84886397589     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxt043     Document Type: Article

References (99)

1. Kavey, R. E., Daniels, S. R., Lauer, R. M., Atkins, D. L., Hayman, L. L. and Taubert, K.; American Heart Association. 2003. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 107:1562.
2. Hansson, G. K. and Hermansson, A. 2011. The immune system in atherosclerosis. Nat. Immunol. 12:204.
3. Wick, G., Perschinka, H. and Millonig, G. 2001. Atherosclerosis as an autoimmune disease: an update. Trends Immunol. 22:665.
4. Silverstein, R. L. and Febbraio, M. 2000. CD36 and atherosclerosis. Curr. Opin. Lipidol. 11:483.
5. Libby, P., Ridker, P. M. and Hansson, G. K. 2011. Progress and challenges in translating the biology of atherosclerosis. Nature 473:317.
6. Tse, K. and Ley, K. 2012. Transforming growth factor-beta: transforming plaque to stability. Eur. Heart. J.
7. Ketelhuth, D. F. and Hansson, G. K. 2011. Cellular immunity, lowdensity lipoprotein and atherosclerosis: break of tolerance in the artery wall. Thromb. Haemost. 106:779.
8. Shimada, K. 2009. Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circ. J. 73:994.
9. Moore, K. J. and Tabas, I. 2011. Macrophages in the pathogenesis of atherosclerosis. Cell 145:341.
10. Shashkin, P., Dragulev, B. and Ley, K. 2005. Macrophage differentiation to foam cells. Curr. Pharm. Des. 11:3061.
11. Zhou, X. and Hansson, G. K. 1999. Detection of B cells and proinflammatory cytokines in atherosclerotic plaques of hypercholesterolaemic apolipoprotein E knockout mice. Scand. J. Immunol. 50:25.
12. Zernecke, A., Shagdarsuren, E. and Weber, C. 2008. Chemokines in atherosclerosis: an update. Arterioscler. Thromb. Vasc. Biol. 28:1897.
13. Andersson, J., Libby, P. and Hansson, G. K. 2010. Adaptive immunity and atherosclerosis. Clin. Immunol. 134:33.
14. Thorp, E., Subramanian, M. and Tabas, I. 2011. The role of macrophages and dendritic cells in the clearance of apoptotic cells in advanced atherosclerosis. Eur. J. Immunol. 41:2515.
15. Thorp, E. and Tabas, I. 2009. Mechanisms and consequences of efferocytosis in advanced atherosclerosis. J. Leukoc. Biol. 86:1089.
16. Gounopoulos, P., Merki, E., Hansen, L. F., Choi, S. H. and Tsimikas, S. 2007. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. Minerva Cardioangiol. 55:821.
17. Lahoute, C., Herbin, O., Mallat, Z. and Tedgui, A. 2011. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat. Rev. Cardiol. 8:348.
18. Stemme, S., Faber, B., Holm, J., Wiklund, O., Witztum, J. L. and Hansson, G. K. 1995. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl Acad. Sci. USA 92:3893.
19. de Boer, O. J., van der Wal, A. C., Verhagen, C. E. and Becker, A. E. 1999. Cytokine secretion profiles of cloned T cells from human aortic atherosclerotic plaques. J. Pathol. 188:174.
20. Grivel, J. C., Ivanova, O., Pinegina, N. et al. 2011. Activation of T lymphocytes in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 31:2929.
21. Afek, A., George, J., Gilburd, B. et al. 2000. Immunization of lowdensity lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J. Autoimmun. 14:115.
22. Zhu, J., Quyyumi, A. A., Rott, D. et al. 2001. Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation 103:1071.
23. Kervinen, H., Huittinen, T., Vaarala, O. et al. 2003. Antibodies to human heat shock protein 60, hypertension and dyslipidemia. A study of joint effects on coronary risk. Atherosclerosis 169:339.
24. Dong, C. 2006. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat. Rev. Immunol. 6:329.
25. Korn, T., Bettelli, E., Oukka, M. and Kuchroo, V. K. 2009. IL-17 and Th17 Cells. Annu. Rev. Immunol. 27:485.
26. Lee, Y. K., Mukasa, R., Hatton, R. D. and Weaver, C. T. 2009. Developmental plasticity of Th17 and Treg cells. Curr. Opin. Immunol. 21:274.
27. Chaudhry, A., Samstein, R. M., Treuting, P. et al. 2011. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34:566.
28. Subramanian, M., Thorp, E., Hansson, G. K. and Tabas, I. 2013. Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J. Clin. Invest. 123:179.
29. Seok, J., Warren, H. S., Cuenca, A. G. et al.; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. 2013. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110:3507.
30. Laurat, E., Poirier, B., Tupin, E. et al. 2001. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104:197.
31. Mallat, Z., Taleb, S., Ait-Oufella, H. and Tedgui, A. 2009. The role of adaptive T cell immunity in atherosclerosis. J. Lipid Res. 50(Suppl.):S364.
32. Elhage, R., Jawien, J., Rudling, M. et al. 2003. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res. 59:234.
33. Whitman, S. C., Ravisankar, P., Elam, H. and Daugherty, A. 2000. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am. J. Pathol. 157:1819.
34. Davenport, P. and Tipping, P. G. 2003. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 163:1117.
35. Hauer, A. D., Uyttenhove, C., de Vos, P. et al. 2005. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 112:1054.
36. Mallat, Z., Corbaz, A., Scoazec, A. et al. 2001. Interleukin-18/ interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ. Res. 89:E41.
37. Buono, C., Binder, C. J., Stavrakis, G., Witztum, J. L., Glimcher, L. H. and Lichtman, A. H. 2005. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc. Natl Acad. Sci. USA 102:1596.
38. Binder, C. J., Hartvigsen, K., Chang, M. K. et al. 2004. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 114:427.
39. Wurtz, O., Bajenoff, M. and Guerder, S. 2004. IL-4-mediated inhibition of IFN-gamma production by CD4+ T cells proceeds by several developmentally regulated mechanisms. Int. Immunol. 16:501.
40. Engelbertsen, D., Andersson, L., Ljungcrantz, I. et al. 2013. T-helper 2 immunity is associated with reduced risk of myocardial infarction and stroke. Arterioscler. Thromb. Vasc. Biol. 33:637.
41. Feng, J., Han, J., Pearce, S. F. et al. 2000. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J. Lipid Res. 41:688.
42. Huang, J. T., Welch, J. S., Ricote, M. et al. 1999. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 400:378.
43. Cornicelli, J. A., Butteiger, D., Rateri, D. L., Welch, K. and Daugherty, A. 2000. Interleukin-4 augments acetylated LDLinduced cholesterol esterification in macrophages. J. Lipid Res. 41:376.
44. Barks, J. L., McQuillan, J. J. and Iademarco, M. F. 1997. TNFalpha and IL-4 synergistically increase vascular cell adhesion molecule-1 expression in cultured vascular smooth muscle cells. J. Immunol. 159:4532.
45. Lee, Y. W., Kuhn, H., Hennig, B., Neish, A. S. and Toborek, M. 2001. IL-4-induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J. Mol. Cell. Cardiol. 33:83.
46. Sasaguri, T., Arima, N., Tanimoto, A., Shimajiri, S., Hamada, T. and Sasaguri, Y. 1998. A role for interleukin 4 in production of matrix metalloproteinase 1 by human aortic smooth muscle cells. Atherosclerosis 138:247.
47. Walch, L., Massade, L., Dufilho, M., Brunet, A. and Rendu, F. 2006. Pro-atherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression. Atherosclerosis. 187:285.
48. King, V. L., Szilvassy, S. J. and Daugherty, A. 2002. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a sitespecific manner in female LDL receptor-/- mice. Arterioscler. Thromb. Vasc. Biol. 22:456.
49. King, V. L., Cassis, L. A. and Daugherty, A. 2007. Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice. Am. J. Pathol. 171:2040.
50. Binder, C. J., Chou, M. Y., Fogelstrand, L. et al. 2008. Natural antibodies in murine atherosclerosis. Curr. Drug Targets 9:190.
51. Horkko, S., Bird, D. A., Miller, E. et al. 1999. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103:117.
52. Butcher, M. and Galkina, E. 2011. Current views on the functions of interleukin-17A-producing cells in atherosclerosis. Thromb. Haemost. 106:787.
53. Erbel, C., Chen, L., Bea, F. et al. 2009. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J. Immunol. 183:8167.
54. Jovanovic, D. V., Di Battista, J. A., Martel-Pelletier, J. et al. 1998. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J. Immunol. 160:3513.
55. Madhur, M. S., Funt, S. A., Li, L. et al. 2011. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler. Thromb. Vasc. Biol. 31:1565.
56. Ley, K., Smith, E. and Stark, M. A. 2006. IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol. Res. 34:229.
57. Cheng, X., Yu, X., Ding, Y. J. et al. 2008. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin. Immunol. 127:89.
58. Smith, E., Prasad, K. M., Butcher, M. et al. 2010. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 121:1746.
59. Eid, R. E., Rao, D. A., Zhou, J. et al. 2009. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 119:1424.
60. Cheng, X., Taleb, S., Wang, J. et al. 2011. Inhibition of IL-17A in atherosclerosis. Atherosclerosis 215:471.
61. Butcher, M. J., Gjurich, B. N., Phillips, T. and Galkina, E. V. 2012. The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. Circ. Res. 110:675.
62. Taleb, S., Romain, M., Ramkhelawon, B. et al. 2009. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J. Exp. Med. 206:2067.
63. Danzaki, K., Matsui, Y., Ikesue, M. et al. 2012. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 32:273.
64. Ray, A., Khare, A., Krishnamoorthy, N., Qi, Z. and Ray, P. 2010. Regulatory T cells in many flavors control asthma. Mucosal Immunol. 3:216.
65. de Boer, O. J., van der Meer, J. J., Teeling, P., van der Loos, C. M. and van der Wal, A. C. 2007. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One 2:e779.
66. Wigren, M., Bjorkbacka, H., Andersson, L. et al. 2012. Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke. Arterioscler. Thromb. Vasc. Biol. 32:2000.
67. Meng, X., Zhang, K., Li, J. et al. 2012. Statins induce the accumulation of regulatory T cells in atherosclerotic plaque. Mol. Med. 18:598.
68. Mallat, Z., Gojova, A., Brun, V. et al. 2003. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation 108:1232.
69. Ait-Oufella, H., Salomon, B. L., Potteaux, S. et al. 2006. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 12:178.
70. Lin, J., Li, M., Wang, Z., He, S., Ma, X. and Li, D. 2010. The role of CD4+CD25+ regulatory T cells in macrophage-derived foam-cell formation. J. Lipid Res. 51:1208.
71. Liu, G., Ma, H., Qiu, L. et al. 2011. Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice. Immunol. Cell Biol. 89:130.
72. Kronenberg, M. and Gapin, L. 2002. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2:557.
73. Nowak, M. and Stein-Streilein, J. 2007. Invariant NKT cells and tolerance. Int. Rev. Immunol. 26:95.
74. Yang, Y., Bao, M. and Yoon, J. W. 2001. Intrinsic defects in the T-cell lineage results in natural killer T-cell deficiency and the development of diabetes in the nonobese diabetic mouse. Diabetes 50:2691.
75. Bobryshev, Y. V. and Lord, R. S. 2005. Co-accumulation of dendritic cells and natural killer T cells within rupture-prone regions in human atherosclerotic plaques. J. Histochem. Cytochem. 53:781.
76. Chan, W. L., Pejnovic, N., Hamilton, H. et al. 2005. Atherosclerotic abdominal aortic aneurysm and the interaction between autologous human plaque-derived vascular smooth muscle cells, type 1 NKT, and helper T cells. Circ. Res. 96:675.
77. Tupin, E., Nicoletti, A., Elhage, R. et al. 2004. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J. Exp. Med. 199:417.
78. Major, A. S., Wilson, M. T., McCaleb, J. L. et al. 2004. Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 24:2351.
79. Nakai, Y., Iwabuchi, K., Fujii, S. et al. 2004. Natural killer T cells accelerate atherogenesis in mice. Blood. 104:2051.
80. van Puijvelde, G. H., van Wanrooij, E. J., Hauer, A. D., de Vos, P., van Berkel, T. J. and Kuiper, J. 2009. Effect of natural killer T cell activation on the initiation of atherosclerosis. Thromb. Haemost. 102:223.
81. Braun, N. A., Covarrubias, R. and Major, A. S. 2010. Natural killer T cells and atherosclerosis: form and function meet pathogenesis. J. Innate Immun. 2:316.
82. Crotty, S. 2011. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29:621.
83. Benagiano, M., D'Elios, M. M., Amedei, A. et al. 2005. Human 60-kDa heat shock protein is a target autoantigen of T cells derived from atherosclerotic plaques. J. Immunol. 174:6509.
84. Koltsova, E. K., Garcia, Z., Chodaczek, G. et al. 2012. Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J. Clin. Invest. 122:3114.
85. Fredrikson, G. N., Hedblad, B., Berglund, G. et al. 2003. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 23:872.
86. Fredrikson, G. N., Soderberg, I., Lindholm, M. et al. 2003. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler. Thromb. Vasc. Biol. 23:879.
87. Fredrikson, G. N., Bjorkbacka, H., Soderberg, I., Ljungcrantz, I. and Nilsson, J. 2008. Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies. J. Intern. Med. 264:563.
88. Wigren, M., Kolbus, D., Duner, P. et al. 2011. Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. J. Intern. Med. 269:546.
89. Herbin, O., Ait-Oufella, H., Yu, W. et al. 2012. Regulatory T-cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 32:605.
90. Sidney, J., Southwood, S., Moore, C. et al. 2013. Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture. Curr. Protoc. Immunol. 18.3.1.
91. Cheng, Y. and Prusoff, W. H. 1973. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099.
92. Gulukota, K., Sidney, J., Sette, A. and DeLisi, C. 1997. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J. Mol. Biol. 267:1258.
93. Alexander, J., Sidney, J., Southwood, S. et al. 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751.
94. Petersen, T. R., Bettelli, E., Sidney, J., Sette, A., Kuchroo, V. and Backstrom, B. T. 2004. Characterization of MHC- and TCR-binding residues of the myelin oligodendrocyte glycoprotein 38-51 peptide. Eur. J. Immunol. 34:165.
95. Choi, J. H., Cheong, C., Dandamudi, D. B. et al. 2011. Flt3 signaling-dependent dendritic cells protect against atherosclerosis. Immunity 35:819.
96. Chyu, K. Y., Zhao, X., Dimayuga, P. C. et al. 2012. CD8+ T cells mediate the athero-protective effect of immunization with an ApoB-100 peptide. PLoS One 7:e30780.
97. Barnden, M. J., Allison, J., Heath, W. R. and Carbone, F. R. 1998. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76:34.
98. Milich, D. R., Hughes, J. L., McLachlan, A., Thornton, G. B. and Moriarty, A. 1988. Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope. Proc. Natl Acad. Sci. USA 85:1610.
99. Wall, K. A., Hu, J. Y., Currier, P., Southwood, S., Sette, A. and Infante, A. J. 1994. A disease-related epitope of Torpedo acetylcholine receptor. Residues involved in I-Ab binding, self-nonself discrimination, and TCR antagonism. J. Immunol. 152:4526.